Here's your full detailed TB-500 page rewrite, ready to paste:
TB-500 (Thymosin Beta-4) — Full Product Page (Detailed Version)
Product Title:
TB-500 (Thymosin Beta-4) — Synthetic Actin-Regulatory Research Peptide
Short Description:
A laboratory-synthesized 43-amino acid synthetic peptide corresponding to the sequence of Thymosin Beta-4 (Tβ4), investigated in preclinical research for actin regulation, cytoskeletal remodeling, cellular migration pathway dynamics, endothelial biology, and angiogenesis-related signaling endpoints. ≥99% Purity, HPLC-Verified. Third-Party CoA Included. For in-vitro laboratory research use only.
Full Product Description:
Overview
TB-500 is a laboratory-synthesized peptide consisting of a 43-amino acid sequence corresponding to Thymosin Beta-4 (Tβ4) — a peptide extensively studied in cytoskeletal and cell-motility research. In experimental biology, thymosin beta peptides are commonly utilized to examine actin regulation, specifically the balance between monomeric (G-actin) and filamentous (F-actin) states, which underlies a wide range of fundamental cellular behaviors.
Within preclinical research systems, TB-500 has been applied in studies investigating cytoskeletal remodeling–dependent processes including cell migration, neurite extension, endothelial cell function, and extracellular matrix (ECM) restructuring. Published experimental literature includes in-vitro assays and controlled animal studies evaluating oxidative stress signaling, angiogenesis-related transcriptional activity, epithelial and stromal repair kinetics, and tissue remodeling endpoints under defined laboratory conditions.
Biochemical Characteristics
- Amino Acid Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser
- Molecular Formula: C₂₁₂H₃₅₀N₅₆O₇₈S
- Molecular Weight: 4,963.44 g/mol
- CAS Registry Number: 77591-33-4
- PubChem CID: 16132341
TB-500 is a non-glycosylated, linear peptide with no disulfide bonds. Its biochemical behavior reflects the actin-binding characteristics of Thymosin Beta-4, supporting its use in studies focused on cytoskeletal organization and actin-dependent signaling network investigation.
Research Applications
TB-500 is utilized exclusively within laboratory research workflows to evaluate cytoskeleton-linked cellular phenotypes and signaling outputs. Common experimental applications include:
Actin Regulation Studies
G-actin sequestration dynamics, F-actin polymerization status assessment, and stress-fiber organization analysis in controlled cell-based experimental systems.
Cell Motility & Adhesion Research
Scratch-wound migration assays, transwell movement studies, and focal adhesion remodeling endpoint analysis under defined laboratory conditions.
Endothelial & Angiogenesis-Related Research
Tube formation model studies, VEGF-axis transcriptional analysis, and vascular remodeling endpoint investigation in controlled preclinical systems.
Oxidative Stress & Innate Signaling Research
Pathway activity assessment under defined cellular stressor conditions in controlled in-vitro research environments.
Neural & Glial Cell Research Models
Neurite morphology endpoint evaluation, support-cell response assessment, and cytoskeletal remodeling dynamics in neural cell research systems.
Host–Pathogen Interaction Studies
Controlled animal model investigations including quantitative microbial load measurements and inflammatory marker profiling endpoints.
All experimental applications are limited to non-clinical research systems designed to explore fundamental biological mechanisms.
Pathway & Mechanistic Context
Thymosin beta peptides are classically characterized as actin-binding regulators that sequester G-actin, influencing the pool of monomers available for filament formation. Because actin dynamics are integral to processes including membrane protrusion, endocytosis, cytokinesis, and mechanotransduction in experimental models, shifts in G-actin/F-actin balance can substantially alter cellular behavior in controlled research systems.
Across preclinical models, TB-4 and TB-500–associated findings have been reported alongside modulation of:
- Angiogenic signaling programs and ECM-associated molecular markers
- Cellular stress-response pathway activity
- Oxidative stress and innate signaling frameworks including pathway-linked mediator assessment
- Viability indicator measurement under controlled experimental stress conditions
Preclinical Research Summary
1. Neural Tissue & Support-Cell Models
In rodent spinal cord injury research models, Thymosin Beta-4 has been evaluated using histological, vascular, and functional outcome measures to assess cellular responses within damaged neural tissue. In neural stem and progenitor cell models derived from spinal tissue, TB-4 has been studied under oxidative stress paradigms, with pathway-level readouts mapped to innate signaling axes including TLR4/MyD88, incorporating measurements of oxidative mediators and cell-viability indicators in vitro.
2. Vascular Biology, Angiogenesis & ECM Remodeling
Preclinical literature documents Thymosin Beta-4 involvement in angiogenesis-associated programs, with reported relationships to VEGF-related signaling and vascular remodeling endpoints. Proposed mechanisms involve coordinated effects on cell migration, extracellular matrix restructuring, and endothelial and pericyte-associated processes, assessed through model-specific molecular and histological analyses.
3. Skin & Appendage Research Models
Mouse studies involving altered Thymosin Beta-4 expression have reported changes in hair follicle-associated phenotypes. Additional investigations have examined its role in stem-cell migration and differentiation readouts within skin and appendage-focused experimental systems.
4. Infection Research Models
In murine models of Pseudomonas aeruginosa–induced keratitis, Thymosin Beta-4 has been studied alongside antibiotic treatment protocols. Reported endpoints include bacterial colony-forming unit (CFU) counts, neutrophil infiltration levels, and oxidative and inflammatory mediator measurements following defined treatment intervals.
5. Cardiovascular & Renal Experimental Systems
Research literature documents Thymosin Beta-4–associated pathway activity in cardiovascular and renal research models, with endpoints including angiogenic remodeling markers, endothelial migration dynamics, inflammatory signaling profiles, and fibrosis-related molecular markers. In myocardial ischemia paradigms, injectable hydrogel systems incorporating collagen and Thymosin Beta-4 have been evaluated using angiogenesis and epicardial cell migration readouts in controlled preclinical study designs.
6. Neurodegeneration-Adjacent Cellular Models
In HT22 neuronal cell experiments involving prion peptide exposure, Thymosin Beta-4 has been examined for its influence on autophagy-related signaling pathways and proteostasis-associated markers under defined in-vitro laboratory conditions.
Overall Research Context
Across preclinical research literature, TB-4 and TB-500 are most frequently studied in the context of actin regulation, cytoskeletal remodeling, migration-related cellular behaviors, stress-response signaling, and tissue remodeling processes. Interpretation of experimental outcomes is inherently model-specific and dependent on study design variables including dose, exposure route, timing, and assay methodology. All content is provided strictly for scientific reference purposes and does not imply suitability for any non-research application.
Form & Analytical Testing
TB-500 is supplied as a synthetic peptide intended for controlled laboratory use. Identity and traceability are supported through sequence verification and registry identifiers including CAS numbers and PubChem records. Standard research-grade qualification practices include:
- HPLC — chromatographic purity assessment and lot consistency verification
- Mass Spectrometry — molecular mass confirmation and identity verification
Purity & Quality
- ≥99% Purity — HPLC Verified
- Independently tested by accredited third-party laboratory
- Certificate of Analysis (CoA) available for every batch
Research Use Only (RUO) Notice
All products are furnished strictly for in-vitro laboratory research use only. These materials are not pharmaceuticals, drugs, or therapeutic agents and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.
